Novel Technique for Urethral Catheterization in Cats & Small Dogs

Dale E. Bjorling, DVM, MS, DACVS
University of Wisconsin-Madison

In the literature

FROM THE PAGE ...

Passage of a urethral catheter in female cats and small female dogs can sometimes be challenging due to patient size. This study describes a novel technique in which a large catheter (ie, 10 Fr in most cats, 18 Fr in dogs) is steriley passed into the vagina of anesthetized female cats and small female dogs (<22 lb [10 kg]) until the tip can no longer be advanced cranially. The open end of the catheter is then reflected dorsally and held in place while a smaller catheter (ie, 5 Fr in cats, 8 Fr in dogs) is inserted beneath the larger catheter and directed along the midline of the vestibule ventrally at an ≈45-degree angle until the catheter advances through the urethral orifice.

The study included 24 cats and 15 dogs anesthetized for ovariohysterectomy. Patients receiving treatment for urinary tract infection, emaciated or obese patients, and patients with abnormal external genitalia were excluded. Catheterizations were performed on a single patient by a board-certified veterinary surgeon with experience in the novel procedure, a board-certified veterinary surgeon with no prior experience using the novel procedure, or a veterinary surgical intern with no prior experience using the novel procedure. Placement of a urethral catheter was also attempted using standard techniques for comparison. The order in which the 2 techniques were performed was randomized. The time required to achieve catheterization was recorded and limited to ≤3 minutes in both techniques. Inability to place the catheter within the timeframe was considered a failure of that technique.

The novel technique was successfully used for urethral catheterization in 19 cats and 12 dogs, with an overall success rate of 31 out of 39 patients.
The novel technique was successfully used for urethral catheterization in 19 cats and 12 dogs, with an overall success rate of 31 out of 39 patients. The median time for placement of the urethral catheter was 48 seconds. Urethral catheters were successfully placed in 12 cats and 5 dogs using standard techniques, with an overall success rate of 17 out of 39 patients; catheters were passed in a median time of 41 seconds. The overall success rate for traditional methods was significantly lower than that of the novel catheterization technique. There were no differences in success or time required to place catheters relative to clinician experience.

These results suggest that use of the novel technique for urethral catheter placement in female cats and small female dogs should be considered.

… TO YOUR PATIENTS

Key pearls to put into practice:

**Placement of a urethral catheter in female cats and small female dogs can be difficult. Multiple unsuccessful attempts to pass a catheter can be frustrating and can cause irritation or damage to the urethra or vagina.**

Results of this study suggest that a novel technique could be successfully performed with minimal prior training. However, it is preferable to practice this technique prior to performing it.

If urethral catheterization is unsuccessful in female cats or small female dogs, further investigation (eg, contrast vaginourethrogram, ultrasonography, endoscopy) should be performed to rule out anatomic barriers to the passage of the urethral catheter.

Suggested Reading


---

**Osurnia**

(florfenicol, terbinafine, betamethasone acetate)

**Otic gel**

For Otic Use in Dogs Only

Do not use in cats

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**BRIEF SUMMARY** (for full prescribing information, see package insert)

**DESCRIPTION:** OSURNIA contains 10 mg florfenicol, 10 mg terbinafine and 1 mg betamethasone acetate per mL, and the inactive ingredients propylene carbonate, glycerol formal, hypromellose, phospholipid, oleic acid and BHT in an off-white to slightly yellow transparent gel.

**INDICATION:** OSURNIA is indicated for the treatment of otitis externa in dogs associated with susceptible strains of bacteria (Sphingomonas puseulivermide and pseudomonas pseudomonas) and yeast (Malassezia pachydermatis).

**DOSAGE AND ADMINISTRATION:** OSURNIA should be administered in the clinic. Clean and dry the external ear canal before administering the initial dose of the product. Administer one dose (1 tube per affected ear) and repeat administration in 7 days. Do not clean the ear canal for 40 days after the initial administration to allow contact of the gel with the ear canal. Cleaning the ear may affect product effectiveness.

**CONTRAINDICATIONS:** Do not use in dogs with known tympanic membrane perforation (see Precautions in the product insert). Do not use in dogs with a hypersensitivity to florfenicol, terbinafine, or corticosteroids.

**WARNINGS:**

**Human Safety Warning:** OSURNIA may cause eye injury and irritation.

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. In case of accidental skin contact, wash area thoroughly with water. Avoid contact to the eyes. In case of accidental eye contact, flush thoroughly with water for at least 15 minutes. If symptoms develop, seek medical advice.

**PRECAUTIONS:** Wear eye protection when administering OSURNIA and restrain the dog to minimize post-application head shaking.

Reducing the potential for splatter of product will help prevent accidental exposure in people and dogs and help to prevent ocular injury. Do not administer orally. The use of OSURNIA in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering this product. Regular monitoring should be performed during treatment. Use of topical corticosteroids has been associated with adrenocortical suppression and hypothalamic-pituitary suppression in dogs (see Animal Safety in the product insert). Use with caution in dogs with impaired hepatic function (see Animal Safety and Adverse Reactions in the product insert). The safe use of OSURNIA in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

**ADVERSE REACTIONS:** The following adverse reactions were reported during the course of a US field study for treatment of otitis externa in dogs treated with OSURNIA in decreasing order of incidence: elevated liver enzymes, vomiting, weight loss (>10% body weight), loss of appetite, ear irrigation, head shaking, and dark urine. To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Dechra Veterinary Products at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

**POST-APPROVAL EXPERIENCE:** The following adverse events are based on post-approval adverse drug experience reporting for OSURNIA.

Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using adverse event data.

In humans, accidental exposure to cornual uclers and other ocular injuries such as eye irritation, burning, stinging, and itching have been reported to occur when the dog shook its head after administration of OSURNIA.

In dogs, the adverse events reported for OSURNIA are presented below in decreasing order of reporting frequency: Deafness, ear discharge, ear irritation and pain, vomiting, head shaking, head tilt, ataxia, vocalization, corneal ulcer, keratoconjunctivitis sicca, myasthenia, lympohocytic rupture, and facial paralysis.

**INFORMATION FOR DOG OWNERS:** Owners should be aware that adverse reactions may occur following administration of OSURNIA in dogs. Owners should observe dog for signs such as deafness, ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge (see Animal Safety and Post-Approval Experience in the product insert).

Owners should also be advised of the potential for ocular exposure if any of the above signs are observed. Owners should also be advised that splatter may occur if the dog shakes its head following administration of OSURNIA which may lead to ocular exposure. A result, eye injuries in humans and dogs have been reported including corneal ulcers.

**EFFECTIVENESS:** Effectiveness was evaluated in 235 dogs with otitis externa. The study was a double-masked field study with a placebo control (vehicle without the active ingredients). One hundred and ninety-five dogs were treated with OSURNIA and seventy-six dogs were treated with the placebo control. All dogs were evaluated for efficacy. Treatment A was administered to the affected ear(s) and repeated 7 days later. Prior to the first administration, the ear(s) were cleaned with saline but prior to the Day 7 administration. Six clinical signs associated with otitis externa were evaluated: pain, erythema, edema, swelling, odor and ulceration. Total clinical scores were assigned for a dog based on the severity of each clinical sign on Days 0, 7, 14, 30 and 45. Success was determined by clinical improvement at Day 45. The success rates of the two groups were significantly different (p = 0.0049). 64.76% of dogs administered OSURNIA were successfully treated, compared to 43.42% of the dogs in the placebo control group.

**STORAGE CONDITIONS:** OSURNIA should be stored under refrigerated conditions between 36° - 46° F (2° - 8° C). To facilitate comfort during administration, OSURNIA may be brought to room temperature and stored for up to three months.

**MANUFACTURER FOR:** Dechra Veterinary Products

7010 W 116th Street, Suite 525

Overland Park, KS 66211 USA

Product of Great Britain.

Approved by FDA under NADA # 1-437

OSURNIA® is a trademark of Dechra Ltd.

All rights reserved.

R 03 2021